In March 2016 Bristol-Myers Squibb (NYSE:BMY) agreed to acquire Padlock to continue the development of medicines targeting protein-arginine deiminases (PADs), enzymes with an important role in the generation of autoantigens, inflammation, and immune complex formation in autoimmune diseases.
Bristol-Myers bags biotech upstart Padlock in $600M autoimmune deal
Padlock Therapeutics – FierceBiotech’s 2015 Fierce 15
Atlas’ Padlock scoops up some GlaxoSmithKline assets in autoimmunity
Padlock Banks $23M with a Fresh Approach to Autoimmune Disease
Déjà Vu For Gilman as New Immunology Startup, Padlock, Gets $23M
Rekindling the Flame
Bristol-Myers bags biotech upstart Padlock in $600M autoimmune deal
Padlock Therapeutics – FierceBiotech’s 2015 Fierce 15
Atlas’ Padlock scoops up some GlaxoSmithKline assets in autoimmunity
Padlock Banks $23M with a Fresh Approach to Autoimmune Disease
Déjà Vu For Gilman as New Immunology Startup, Padlock, Gets $23M
Rekindling the Flame
Location: United States, Massachusetts, Cambridge
Total raised: $23M
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 18.12.2014 | Series A | $23M | - |
Mentions in press and media 2
| Date | Title | Description |
| 18.12.2014 | Padlock Therapeutics Raises $23M in Series A Financing | Padlock Therapeutics, a Cambridge, Massachusetts-based biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, raised $23m in Series A financing. The round was led by Atlas Venture. The company plans t... |
| 18.12.2014 | Padlock Therapeutics Secures $23M Series A | CAMBRIDGE, MA, Biotechnology company dedicated to creating new medicines for destructive autoimmune diseases, today announced that the company raised $23 million in a Series A financing. >> Click here for more funding data on Padlo... |